BioLineRx Ltd. (BLRX)Healthcare | Biotechnology | Hevel Modi'in, Israel | NasdaqCM
3.10 USD
+0.01
(0.324%)
⇧
(July 13, 2026, 4 p.m.
EDT)
After hours: 3.10 |
Hot Take ↕ | July 11, 2026, 6:31 a.m. EDT
BioLineRx presents a classic biotech value trap where aggressive analyst price targets ($17.50 mean) clash violently with deteriorating business fundamentals. The company is burning cash rapidly, with operating cash flow of -$7.76 million and free cash flow of -$5.49 million, while returning negative equity (-46.7%) and assets (-16.6%). Although revenue growth is technically positive at 87%, this masks a catastrophic collapse in share price; the stock has lost 99% of its value over the last nine years, driven by five consecutive years of negative annual returns. The recent two-year decline confirms a structural deterioration in market valuation. There is no dividend to provide income, and the balance sheet, while not insolvent yet, is fragile under the weight of continuous losses. The disconnect between the lofty analyst consensus and the reality of a shrinking, cash-burning entity makes this a high-risk speculative play rather than a viable investment. |
| Model | MAE |
|---|---|
| AutoETS ✓ | 0.335914 |
| MSTL | 0.342198 |
| AutoTheta | 0.417425 |
| AutoARIMA | 0.467502 |
Forecast horizon: 45 days | Selected: AutoETS
| Forecast Reliability | |
|---|---|
| Score | 37% |
| H-stat | 1.49 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.681 |
| Excess Kurtosis | 0.34 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 43.533 |
| Revenue per Share | 0.6 |
| Market Cap | 13,948,174 |
| Trailing P/E | Infinity |
| Forward P/E | -4.84 |
| Beta | 0.62 |
| Website | https://www.biolinerx.com |
As of July 11, 2026, 6:31 a.m. EDT: Speculator positioning is extremely thin and non-directional. Call volume is negligible across all expirations, with open interest concentrated at the money ($5 strike) rather than showing a distinct bullish or bearish skew. The lack of put activity suggests no significant hedging demand, while the sparse call data indicates a lack of speculative conviction in either direction.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.3425532 |
| Address1 | Modi’in Technology Park |
| Address2 | 2 HaMa’ayan Street |
| All Time High | 4,122.0 |
| All Time Low | 2.15 |
| Ask | 2.31 |
| Ask Size | 1 |
| Average Daily Volume10 Day | 31,190 |
| Average Daily Volume3 Month | 54,095 |
| Average Volume | 54,095 |
| Average Volume10Days | 31,190 |
| Beta | 0.62 |
| Bid | 2.2 |
| Bid Size | 1 |
| Book Value | 3.6 |
| City | Hevel Modi'in |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | Israel |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 3.1 |
| Current Ratio | 1.584 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 3.18 |
| Day Low | 2.98 |
| Debt To Equity | 43.533 |
| Dividend Date | 1,563,148,800 |
| Earnings Call Timestamp End | 1,779,885,000 |
| Earnings Call Timestamp Start | 1,779,885,000 |
| Earnings Timestamp | 1,779,885,000 |
| Earnings Timestamp End | 1,786,624,200 |
| Earnings Timestamp Start | 1,786,624,200 |
| Ebitda | -10,750,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -0.871 |
| Enterprise To Revenue | 6.682 |
| Enterprise Value | 9,368,208 |
| Eps Current Year | -0.93 |
| Eps Forward | -0.64 |
| Eps Trailing Twelve Months | 0.0 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 972 8 642 9101 |
| Fifty Day Average | 3.1526 |
| Fifty Day Average Change | -0.052600145 |
| Fifty Day Average Change Percent | -0.016684687 |
| Fifty Two Week Change Percent | -34.25532 |
| Fifty Two Week High | 4.86 |
| Fifty Two Week High Change | -1.7600002 |
| Fifty Two Week High Change Percent | -0.36213994 |
| Fifty Two Week Low | 2.15 |
| Fifty Two Week Low Change | 0.9499998 |
| Fifty Two Week Low Change Percent | 0.44186035 |
| Fifty Two Week Range | 2.15 - 4.86 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,311,773,400,000 |
| Float Shares | 4,164,336 |
| Forward Eps | -0.64 |
| Forward P E | -4.84375 |
| Free Cashflow | -5,490,125 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 20 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.79244006 |
| Gross Profits | 1,111,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.03908 |
| Held Percent Institutions | 0.00449 |
| Implied Shares Outstanding | 4,499,411 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,738,195,200 |
| Last Split Factor | 1:40 |
| Long Business Summary | BioLineRx Ltd., a biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes GLIX1, an oral, small molecule targeting DNA damage response in glioblastoma and other cancers; and APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel. |
| Long Name | BioLineRx Ltd. |
| Market | us_market |
| Market Cap | 13,948,174 |
| Market State | POSTPOST |
| Max Age | 86,400 |
| Message Board Id | finmb_5015080 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -7,903,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 13,123,231 |
| Number Of Analyst Opinions | 2 |
| Open | 2.91 |
| Operating Cashflow | -7,763,000 |
| Operating Margins | -6.29769 |
| Payout Ratio | 0.0 |
| Phone | 972 8 642 9100 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 3.1 |
| Post Market Time | 1,783,973,404 |
| Previous Close | 3.09 |
| Price Eps Current Year | -3.3333333 |
| Price Hint | 4 |
| Price To Book | 0.8611111 |
| Price To Sales Trailing12 Months | 9.948769 |
| Profit Margins | 0.0 |
| Quick Ratio | 1.413 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | 0.00999999 |
| Regular Market Change Percent | 0.323624 |
| Regular Market Day High | 3.18 |
| Regular Market Day Low | 2.98 |
| Regular Market Day Range | 2.98 - 3.18 |
| Regular Market Open | 2.91 |
| Regular Market Previous Close | 3.09 |
| Regular Market Price | 3.1 |
| Regular Market Time | 1,783,972,801 |
| Regular Market Volume | 12,582 |
| Return On Assets | -0.16554001 |
| Return On Equity | -0.46723 |
| Revenue Growth | 0.871 |
| Revenue Per Share | 0.6 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 4,351,357 |
| Shares Percent Shares Out | 0.031400003 |
| Shares Short | 136,651 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 166,615 |
| Short Name | BioLineRx Ltd. |
| Short Percent Of Float | 0.031400003 |
| Short Ratio | 6.99 |
| Source Interval | 15 |
| Symbol | BLRX |
| Target High Price | 23.0 |
| Target Low Price | 12.0 |
| Target Mean Price | 17.5 |
| Target Median Price | 17.5 |
| Total Cash | 17,353,000 |
| Total Cash Per Share | 3.988 |
| Total Debt | 9,070,000 |
| Total Revenue | 1,402,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | 0.0 |
| Trailing P E | Infinity |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 3.08285 |
| Two Hundred Day Average Change | 0.017149925 |
| Two Hundred Day Average Change Percent | 0.00556301 |
| Type Disp | Equity |
| Volume | 12,582 |
| Website | https://www.biolinerx.com |
| Zip | 7,177,871 |